Trials / Conditions / Classic Hodgkin Lymphoma

Classic Hodgkin Lymphoma

23 registered clinical trials studyying Classic Hodgkin Lymphoma — 9 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible NCT07275216	City of Hope Medical Center	Phase 2
Not Yet Recruiting	ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma NCT07021989	Michael Spinner, MD	Phase 2
Recruiting	Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With A NCT06745076	University of Washington	Phase 2
Recruiting	A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma NCT06642792	Akeso	Phase 1 / Phase 2
Recruiting	MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma NCT06377540	Masonic Cancer Center, University of Minnesota	Phase 2
Not Yet Recruiting	A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgki NCT06465446	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.	Phase 3
Active Not Recruiting	Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma NCT06164275	Northwestern University	Phase 2
Recruiting	Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma NCT05949931	Sun Yat-sen University	Phase 2
Recruiting	A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma NCT05705531	Children's Oncology Group	—
Recruiting	A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies NCT05955105	Innolake Biopharm	Phase 1 / Phase 2
Active Not Recruiting	Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma NCT04788043	Stanford University	Phase 2
Unknown	Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas NCT05833984	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.	Phase 1 / Phase 2
Terminated	A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents Wi NCT05179603	Sanofi	Phase 2
Active Not Recruiting	Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly NCT03907488	National Cancer Institute (NCI)	Phase 3
Active Not Recruiting	Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma NCT03712202	City of Hope Medical Center	Phase 2
Active Not Recruiting	Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II NCT03233347	Academic and Community Cancer Research United	Phase 2
Active Not Recruiting	Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgki NCT03057795	City of Hope Medical Center	Phase 2
Active Not Recruiting	Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma NCT02758717	Academic and Community Cancer Research United	Phase 2
Active Not Recruiting	Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage I NCT02166463	National Cancer Institute (NCI)	Phase 3
Completed	Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin NCT01771107	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Brentuximab Vedotin with Adriamycin, Vinblastine and Dacarbazine for Patients Aged 18-59 Years with Untreated NCT06857500	Federico II University	—
Completed	Liposomal Doxorubicin-containing Front-line Treatment in Elderly Patients With HL (HL-MVD) NCT06235047	Federico II University	—
Completed	Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin NCT00654732	M.D. Anderson Cancer Center	Phase 2